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Nasal continuous positive airway pressure:
influence on digital volume pulse in
obstructive sleep apnoea patients
Alexandra Scholze*,#,", Stephanie Lamwers+, Martin Tepel*,#," and Bernd M. Sanner+
ABSTRACT: Obstructive sleep apnoea (OSA) is linked to increased cardiovascular risk. This risk
can be reduced by nasal continuous positive airway pressure (nCPAP) treatment. As OSA is
associated with an increase of several vasoconstrictive factors, we investigated whether nCPAP
influences the digital volume pulse wave.
We performed digital photoplethysmography during sleep at night in 94 consecutive patients
who underwent polysomnography and 29 patients treated with nCPAP. Digital volume pulse
waves were obtained independently of an investigator and were quantified using an algorithm for
continuous automated analysis.
In patients with OSA and an apnoea/hypopnoea index (AHI) of .10 events?h-1, a significant
vasoconstriction was observed during the night (p,0.0001 by Friedman’s test). A significant positive
correlation existed between vasoconstriction and AHI (Spearman correlation, r50.27; p,0.01; n594)
and the arousal index (Spearman correlation, r50.21; p,0.05; n594). After 6 months of nCPAP treat-
ment, the AHI was significantly reduced from 27¡3 events?h-1 to 4¡2 events?h-1 (each n529; p,0.001)
and vasoconstriction during the night was significantly reduced from 10¡3% to 3¡1% (p,0.01).
We show changes in the reflective index during the night consistent with vasoconstriction in
patients with OSA, which are significantly reduced after 6 months of nCPAP treatment.
KEYWORDS: Digital volume pulse wave, nasal continuous positive airway pressure, obstructive
sleep apnoea, vasoconstriction
P
atients with symptomatic obstructive
sleep apnoea (OSA) are characterised by
repeated episodes of upper-airway occlu-
sion during sleep, with consequent excessive
daytime sleepiness and impairment of quality of
life [1, 2]. Patients with untreated OSA have
increased cardiovascular morbidity and mortality,
whereas treatment with nasal continuous positive
airway pressure (nCPAP) reduces cardiovascular
risk in these patients [3, 4]. The pathophysiology
of OSA and its adverse effects on the cardiovas-
cular system remain complex. Apnoea and
hypopnoea cause temporary elevations in blood
pressure in association with hypoxia and sympa-
thetic activation. Intermittent hypoxia causes
sympathetic nervous system overactivity, activa-
tion of the renin–angiotensin system, oxidative
stress and endothelial dysfunction [5–7]. The
digital volume pulse provides additional informa-
tion to peripheral pressure pulse. Its contour
is determined mainly by characteristics of the
systemic circulation, including pressure wave
reflection. Increased pulse wave reflection con-
tributes to disturbances of heart-vessel coupling
and finally to the development of cardiovascular
disease [8, 9].
Treatment of OSA is aimed mainly at preventing
the collapse of upper airways, reducing the
number of episodes of apnoea and hypopnoea,
and reducing the number of oxyhaemoglobin
desaturation episodes during sleep. Treatment
using nCPAP reduces the episodes of apnoea and
hypopnoea. Several, but not all, investigators
have shown that nCPAP reduces elevated blood
pressure [10–12]. Beneficial effects of nCPAP
treatment also include reduced activation of
sympathetic nervous system [13, 14]. However,
there are very limited data on arterial vascular
behaviour during nCPAP treatment. We there-
fore performed noninvasive monitoring of the
digital volume pulse wave during the night in
OSA with and without nCPAP treatment.
METHODS
Patients
We prospectively investigated the digital volume
pulse wave in 94 consecutive patients with
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suspected obstructive sleep-related breathing disorders who
were admitted to our sleep laboratory through unselected
referral from primary or secondary care physicians. Infor-
mation about sleep history was recorded at baseline and at the
time of the final polysomnographic studies. Subjects were
studied in a quiet, temperature-controlled room.
The study protocol was approved by the local ethics committee
(University of Bochum, Bochum, Germany). Written informed
consent was obtained from all patients before entry into the
study.
Polysomnography
94 consecutive patients underwent overnight polysomnogra-
phy for screening for OSA syndrome according to standar-
dised methods [15–17]. According to the patient’s bedtime
behaviour, polysomnography and digital photoplethysmogra-
phy were individually started and finished to allow undis-
turbed sleep. Baseline measurements were performed with
awake patients lying in the supine position before the start of
the polysomnography.
An 18-channel polysomnographic recording system (SOHNOlab;
Weinmann, Hamburg, Germany) was used to assess sleep state
and respiratory and cardiac variables. Continuous recordings
included electroencephalography, electro-oculography, electro-
cardiography, and submental and leg electromyography. The
thoracic/abdominal respiratory movements were detected using
standard belts with piezoelectric sensors (Weinmann’s Somnolab
equipment).
Sleep was staged manually using standard methods [15].
Arterial oxyhaemoglobin saturation, oral and nasal airflow,
tracheal sounds, and rib-cage and abdominal respiratory
motion were used to assess episodes of sleep-disordered
breathing. Polysomnography records were inspected visually
in 30-s periods for episodes of abnormal sleep, breathing and
oxygenation. According to the commonly used clinical criteria,
a breathing event during objectively measured sleep was
defined as abnormal if either a complete cessation of airflow
lasting o10 s took place (apnoea) or a reduction in respiratory
airflow of o50% of the airflow lasting .10 s associated with
either an arousal or a desaturation of .4% could be discerned
(hypopnoea). For the detection of apnoeas/hypopnoeas, respira-
tory flow nasal cannulas were used.
Obstructive apnoea was defined as the absence of airflow in
the presence of paradoxical chest-wall motion. The apnoea/
hypopnoea index (AHI) was defined as the average number
of episodes of apnoea and hypopnoea events per hour of
objectively measured sleep and was the summary measure-
ment of the occurrence of sleep-disordered breathing. The
oxygen desaturation index (ODI) was calculated by dividing
the total number of oxygen desaturations by the total sleep
time, with desaturation defined as a o10 s reduction in oxygen
saturation o4% of baseline.
In 29 patients with symptomatic OSA, nCPAP treatment was
begun. Patients were advised to retain their usual behaviours,
including diet and daily activity. Patients were educated by
trained personnel to use their continuous postitive airway
pressure (CPAP) device as recommended.
CPAP treatment was performed using devices from Respironics
(Murrysville, PA, USA) and Weinmann. Commercially available
masks were used and the optimum size was determined
individually before treatment. All CPAP titrations were per-
formed in hospital during a second laboratory polysomnography
night attended by trained personnel. The majority of patients
(n523) received conventional CPAP with a fixed pressure; four
patients received CPAP with expiratory pressure relief technol-
ogy and two patients received auto-positive airway pressure
(PAP). Conventional CPAP titration was performed manually,
started at 4 cmH2O and increased in steps of 1 cmH2O until
removal of apnoeas, hypopnoeas, flow limitations, oxygen
desaturations and snoring in all sleep stages and body positions
had been acheived. The pressure obtained thereby was con-
sidered to be the optimal. Using expiratory relief technology, the
expiratory PAP applied can be kept below the CPAP. For auto-
PAP, the minimal pressure was kept at 5 cmH2O (pressure range
5–14 cmH2O). The pressure was set to start automatically after
20 min of adaptation. The devices used monitored snoring, flow
and impedance. These parameters are used to detect respiratory
events and the pressure is adjusted automatically. The automatic
pressure profiles of the devices were considered acceptable if the
recording period of the auto-PAP device was o6 h, the mean
leak was ,0.4 L?s-1 and the total sleep time was o5 h. Patients
reported proper adherence to CPAP therapy. None of the
patients interrupted CPAP therapy during the 6-month interval.
Another polysomnographic evaluation was performed 6 months
after starting nCPAP treatment.
Digital photoplethysmography
Digital volume pulse waves were continuously quantified by the
reflective index obtained by noninvasive digital photoplethysmo-
graphy and an algorithm for continuous, investigator-indepen-
dent, automatic analysis. The reflective index was determined
according to SCHOLZE et al. [18] with minor modifications. Digital
volume pulse waves were measured by the transmission of red
and infrared light through the finger pulp of the third digit using a
conventional pulse oximeter with a sampling frequency of 300 Hz,
which is then further processed by the internal software at a
frequency of 25 Hz. The pulsatile component results in a reduction
of transmitted light due to the accompanying increase of optical
density and path length of the illuminated tissue. The changes in
light intensity are measured by the photodetector and correlate to
the digital volume pulse wave. The maximum of each digital
volume pulse wave is determined automatically and set to 100.
The reflective index was calculated from the mean of the 5th to the
10th data point after the maximum of the digital volume pulse
wave. This area covers the diastolic shoulder region to the dicrotic
wave, which is in part formed by pulse waves reflected back from
peripheral vascular sites of impedance mismatch. As indicated in
our previous studies, short-term changes of the reflective index
reflect vasoconstriction or vasodilatation [18, 19]. Earlier studies
from our group indicated that the reflective index shows a
significant positive correlation with invasively determined sys-
temic vascular resistance by pulmonary artery catheter (Spearman
correlation, r50.64, p,0.01, n520). In mechanically ventilated ICU
patients under anaesthesia with midazolam and fentanyl, there
was a significant correlation between lower pH in the arterial
blood gas analysis and vasodilation indicated by a lower reflective
index (Spearman correlation, r50.22, p,0.05; n5102) but not with
arterial oxygen tension or arterial carbon dioxide tension.
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Data of the reflective index obtained from all digital volume
pulse waves were averaged every 2.5 min. The reflective index
values shown in figures 2 and 4 and used for the statistical
analyses were obtained at every full hour between midnight
and 05.00 h in all patients and, therefore, give the respective
reflective indices at a given time of day.
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FIGURE 1. Determination of the reflective index by fingertip photoplethysmography. a) Typical digital volume pulse waves obtained by photoplethysmography during
20 s are shown. Pulse waves were measured by the transmission of red and infrared light through the finger pulp. b) One typical pulse wave is depicted. The maximum of the
digital pulse wave was determined. The reflective index was calculated from the mean of the 5th to the 10th data point after the maximum of the digital pulse wave (shaded
area) covering the typical ‘‘shoulder region’’ of the diastolic pulse wave decay. c) Regression curve for first and second measurements of the reflective index. Spearman
correlation, r50.92; p,0.001; n530. d) Bland–Altman plot quantifying the average discrepancy between two measurements; the bias and 95% limit of agreement are
indicated by lines. e) Bar graph showing summary data of the reflective index under resting conditions and during cold-pressure test in healthy subjects. Data are presented
as mean¡SEM (n53). f) Bar graph showing summary data of the reflective index under resting conditions and during apnoea in healthy subjects. *: p,0.05 compared to
resting conditions.
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Statistics
Descriptive statistics for continuous variables are given as
mean¡SEM. Differences between groups were analysed by
nonparametric Mann–Whitney test. Relationships between
parameters were assessed using nonparametric partial Spear-
man correlations. Reproducibility data are given as Bland–
Altman plots that depict percentage differences between two
measurements plotted against the mean of two measurements.
Bias and 95% limit of agreement are given. Changes of the
reflective index during the night were analysed by nonpara-
metric Friedman’s test with Dunn’s multiple comparison post
hoc test. Analyses were performed with GraphPad prism
software (version 5.0, GraphPad Software, San Diego, CA,
USA). All statistical tests were two-sided. A two-sided p-value
of ,0.05 was considered to indicate statistical significance.
RESULTS
Digital volume pulse waves and the diastolic shoulder region
used for the determination of the reflective index are depicted in
figures 1a and b. To demonstrate the reliability of reflective index
measurements repeated determinations were performed (figs 1c
and d). There was a good agreement between the first and the
second determination of the reflective index (n530; r50.92;
p,0.001). Analysing the data according to Bland–Altman con-
firmed a good reproducibility of measurements (bias, -0.1%; 95%
limit of agreement, -5.5–5.4%). To illustrate how vasoconstriction
results in an increased reflective index, digital volume pulse
waves were measured using photoplethysmography during
systemic vasoconstriction induced by cold-pressure tests in
healthy subjects. As shown in figure 1e, the reflective index
significantly increased during cold-pressure tests from 100¡1%
to 112¡1% arbitrary units (n53; p,0.05) indicating vasoconstric-
tion. In healthy subjects, voluntary apnoea significantly increased
the reflective index from 100¡4% to 114¡5% arbitrary units
(p,0.05), consistent with vasoconstriction during apnoea. During
apnoea there was also an increase of muscle sympathetic nerve
activity (18) from 9 to 28 bursts?min-1.
The clinical, biochemical and polysomnographic characteristics
of 94 patients that underwent polysomnography for screening
of OSA are shown in table 1. The changes of the reflective index
during the night for all 94 patients are summarised in figure 2a.
The baseline reflective index (100%) was obtained when patients
were awake lying in the supine position at the start of the
polysomnography. In patients with an AHI ,10 events?h-1, no
significant change of the reflective index was observed during
the night (n529; p.0.05; fig. 2b). After the exclusion of females,
the results remained unchanged (n520; p.0.05). In contrast, 65
patients had OSA with an AHI.10 events?h-1. In these patients,
the reflective index significantly increased to 109¡2% during
the night (n565; p,0.0001; fig. 2b). In the subgroup of males
with AHI .10 events?h-1, the reflective index significantly
increased to 109¡2% (n550; p,0.0001). We observed a
significant correlation between the AHI and the change of the
reflective index during the night (r50.27; p50.01; n594). After
the exclusion of females, this correlation remained significant
(r50.29; p50.01; n570). The arousal index was also significantly
associated with the change of the reflective index during the
night (r50.21, p50.03, n594; and r50.27, p50.02, n570 for
males only). With increasing AHI or arousal index, an increased
reflective index was observed, consistent with an increased
vasoconstriction in more severe OSA.
From a cardiovascular point of view, oxygen desaturation
events .4% during sleep are of special interest; therefore, ODI
.4% was also analysed. There was a significant correlation
between the ODI and the change of the reflective index during
the night (r50.22; p50.02; n5119). The same correlation was
found in the subgroup of male patients (r50.25; p50.02; n587).
To obtain information about the influence of sleep stage on the
reflective index, we analysed the reflective index in relation to
sleep stage at 01.00 h. Sleep stages were determined visually
according to RECHTSCHAFFEN and KALES [20]. Delta sleep
comprises sleep stages 3 and 4. We found a significantly
higher reflective index, consistent with higher vasoconstric-
tion, in sleep stage 1 compared with rapid eye movement
(REM) sleep (n594; p,0.05; fig. 3).
Of the 94 patients that underwent polysomnography, 13 patients
had an AHI ,5, 19 patients were found to have an AHI .5 but
TABLE 1 Clinical and biochemical characteristics of 94
patients that underwent polysomnography
Characteristic AHI,10 AHI.10 p-value
Subjects n 29 65
Age yrs 57¡2 60¡2 0.26
Male 20 (69) 50 (77) 0.45
Body mass index kg?m-2 27.8¡1.0 29.1¡0.6 0.31
Comorbidities
Diabetes 4 (14) 9 (14) 1.00
Hypertension 14 (48) 34 (52) 0.82
CVD 10 (35) 18 (28) 0.63
Smoking 12 (41) 18 (28) 0.23
Systolic blood pressure mmHg 132¡5 136¡3 0.27
Diastolic blood pressure mmHg 84¡3 84¡2 0.67
Pulse pressure mmHg 48¡4 53¡2 0.21
Leukocytes cells?nL-1 7.9¡0.4 7.6¡0.3 0.63
Haemoglobin g?dL-1 14.8¡0.3 14.5¡0.2 0.51
Platelets cells?nL-1 263¡10 259¡9 0.53
Serum creatinine mg?dL-1 1.0¡0.0 1.0¡0.0 0.45
Serum sodium mmol?L-1 140¡1 140¡0 0.83
Serum potassium mmol?L-1 4.2¡0.1 4.1¡0.1 0.43
Serum calcium mmol?L-1 2.40¡0.03 2.35¡0.01 0.07
Glucose mmol?L-1 6.9¡0.6 7.6¡0.4 0.15
Total cholesterol mg?dL-1 212¡9 215¡6 0.94
Triglycerides mg?dL-1 152¡20 211¡20 0.09
C-reactive protein mg?dL-1 0.6¡0.3 0.4¡0.1 0.19
Medication
ACE/AT 11 (38) 24 (37) 1.00
b-blockers 8 (28) 19 (29) 1.00
Calcium channel inhibitors 3 (10) 10 (15) 0.75
Diuretics 8 (28) 16 (25) 0.80
Antiplatelet drugs 7 (24) 20 (31) 0.62
Data are presented as mean¡SEM or n (%), unless otherwise stated. CVD:
presence of or a history of coronary artery disease, stroke or peripheral arterial
vascular disease; ACE/AT: angiotensin-converting enzyme inhibitors/angioten-
sin receptor antagonists. Patients were grouped according to their respective
apnoea/hypopnoea index (AHI).
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were asymptomatic for OSA, and 62 patients were symptomatic
and in need of treatment. Asymptomatic patients reported no
significant daytime sleepiness (Epworth Sleepiness Scale (ESS)
,10), insomnia, subjective sleep disturbances, snoring or other
OSA-associated symptoms.
Of the 62 patients for whom nCPAP treatment was recom-
mended after the polysomnography screening, only 29 patients
were available to follow-up due to administrative restrictions.
Those patients and asymptomatic patients were compared and
are characterised in table 2.
In 29 patients with symptomatic OSA, nCPAP treatment was
started and polysomnography was repeated after 6 months.
CPAP adherence was measured as number of CPAP hours per
night recorded as machine run time from the time counter
internal to the CPAP device. Mean CPAP adherence was
5.6¡0.4 h?night-1. The clinical, biochemical and polysomno-
graphic characteristics of CPAP treated patients are shown in
table 3. After nCPAP treatment, the AHI was significantly
reduced from 24¡4 to 4¡2 events?h-1 (p,0.001). In the
subgroup of male patients, the AHI was significantly reduced
from 26¡4 to 5¡3 events?h-1 (n520, p,0.001) after nCPAP
treatment. The ODI .4% was reduced by nCPAP from 26¡3
in all treated patients and 27¡4 in male patients to 0¡0,
respectively (p,0.0001).
Before nCPAP treatment in 29 patients with symptomatic OSA,
the reflective index significantly increased during the night to
110¡3% at 05.00 h in the morning, indicating vasoconstriction
(n529; p,0.001; fig. 4a). In the subgroup of male patients with
symptomatic OSA, the reflective index significantly increased
to 109¡2% (n520; p,0.01).
After 6 months of nCPAP treatment, the significant increase of
the reflective index during the night could no longer be observed
(n529; p.0.05; fig. 4b). The same result was obtained in the
subgroup of male patients (n520; p.0.05). These data are in line
with the notion that the successful therapy of OSA by nCPAP was
accompanied by a reduction of the reflective index consistent
with reduced vasoconstriction during the night.
DISCUSSION
The present study shows that patients with symptomatic OSA
exhibited a significantly increased reflective index consistent
with vasoconstriction during sleep at night. The severity of
OSA as quantified by the AHI was directly associated with the
increase in vasoconstriction. The successful treatment of OSA
using nCPAP significantly reduced vasoconstriction, provid-
ing one possible explanation for beneficial effects of nCPAP
therapy on cardiovascular morbidity in patients with OSA.
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FIGURE 2. Reflective index in patients that underwent polysomnography. a)
Bar graph showing the reflective index in all 94 patients that underwent
polysomnography for screening of obstructive sleep apnoea. ***: p,0.001 by
Friedman test with Dunn’s multiple comparison post hoc test compared with
patients awake in the lying position before the start of the polysomnography. b)
Comparison of the reflective index in 29 patients with an apnoea/hypopnoea index
(AHI) of ,10 events?h-1 and 65 patients with an AHI of .10 events?h-1 during the
night. ***: p,0.0001 by Friedman test with Dunn’s multiple comparison post hoc
test compared with patients awake in the lying position before the start of the
polysomnography.
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FIGURE 3. Reflective index values in relation to patients’ sleeping stage at
01.00 h. Bar graph showing summary data for reflective indices at sleep stages W
(awake), S1, S2, S3+S4 (delta sleep) and rapid eye movement (REM) in 94 patients
that underwent polysomnography screening. Data are given as a percentage of the
reflective index of patients awake in the lying position before the start of the
polysomnography. *: p,0.05 by Kruskal–Wallis test with Dunn’s multiple
comparison post hoc test. Sleep stage 1 showed a significantly higher reflective
index compared with REM sleep, consistent with a higher vasoconstriction in sleep
stage 1.
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In previous investigations, it was shown that an ODI o4% was
associated with prevalent cardiovascular disease in a large
community sample of middle-aged and older subjects [21]. In
our study population with a high prevalence of sleep-
disordered breathing, we found a significant correlation
between the ODI .4% and the change of the reflective index
during the night. Higher oxygen desaturation indices were
associated with a more pronounced increase of the reflective
index consistent with more pronounced vasoconstriction
during the night. These findings suggest that changes of the
reflective index during the night may add information for the
assessment of cardiovascular risk in these patients.
TABLE 2 Characteristics of 19 asymptomatic and 29 symptomatic patients with obstructive sleep apnoea (OSA)
Characteristic Asymptomatic OSA Symptomatic OSA p-value
Subjects n 19 29
AHI 14¡2 27¡3 ,0.01
Arousal index# 11¡1 14¡2 0.22
Sleep efficiency % 76¡3 76¡2 0.96
Stage wake min 102¡16 103¡9 0.59
Total sleep time min 301¡14 316¡8 0.43
Sleep stage 1 % of total sleep time 9.7¡2.4 10.9¡2.9 0.89
Sleep stage 2 % of total sleep time 53.5¡3.1 57.6¡3.2 0.25
Delta sleep stage 3+4 % of total sleep time 24.0¡2.7 19.9¡2.1 0.27
Sleep stage REM % of total sleep time 12.8¡1.5 11.6¡1.4 0.57
Minimum nocturnal Sa,O2 % 83¡1 77¡2 ,0.05
Mean nocturnal Sa,O2 % 94¡0 93¡0 ,0.05
Sa,O2,90% % 5¡2 19¡4 ,0.05
ESS 5¡1 10¡2 0.08
ODI 12¡3 26¡3 ,0.01
Change of reflective index" during the night % of awake value 5¡2 10¡3 0.17
Data are presented as mean¡SEM, unless otherwise stated. AHI: apnoea/hypopnoea index (mean number of episodes of apnoea and hypopnoea per hour of sleep);
REM: rapid eye movement; Sa,O2: arterial oxygen saturation; ESS: Epworth Sleepiness Scale; ODI: oxygen desaturation index.
#: the arousal index is the mean number of
arousal reactions per hour of sleep; ": reflective index at 05.00 h is given as percentage of the reflective index of the patient awake in the lying position before the start of
the polysomnography.
TABLE 3 Characteristics of 29 patients with obstructive sleep apnoea before and after nasal continuous positive airway pressure
(nCPAP) treatment
Characteristic Before nCPAP After nCPAP p-value
Subjects n 29 29
AHI 27¡3 4¡2 ,0.0001
Arousal index# 14¡2 10¡1 ,0.05
Sleep efficiency % 76¡2 81¡4 ,0.05
Stage wake min 103¡9 66¡9 ,0.01
Total sleep time min 316¡8 349¡17 ,0.01
Sleep stage 1 % of total sleep time 10.9¡2.9 5.6¡1,7 0.16
Sleep stage 2 % of total sleep time 57.6¡3.2 52.6¡3.1 0.35
Delta sleep stage 3+4, % of total sleep time 19.9¡2.1 27.6¡2.8 ,0.05
Sleep stage REM % of total sleep time 11.6¡1.4 14.2¡1.4 0.17
Minimum nocturnal Sa,O2 % 77¡2 86¡1 ,0.0001
Mean nocturnal Sa,O2 % 93¡0 94¡0 ,0.0001
Sa,O2 ,90% % 19¡4 4¡1 ,0.0001
ODI 26¡3 0¡0 ,0.0001
Change of reflective index" during the night % of awake value 10¡3 6¡4 ,0.05
Data are presented as mean¡SEM, unless otherwise stated. AHI: apnoea/hypopnoea index (mean number of episodes of apnoea and hypopnoea per hour of sleep);
REM: rapid eye movement; Sa,O2: arterial oxygen saturation; ODI: oxygen desaturation index.
#: the arousal index is the mean number of arousal reactions per hour of
sleep; ": reflective index at 05.00 h is given as percentage of the reflective index of the patient awake in the lying position before the start of the polysomnography.
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Several mechanisms have been described in patients with OSA
that can result in increased vasoconstriction, finally leading to
progression of cardiovascular disease. First, increased sympa-
thetic activation induced by nocturnal hypoxia has been
reported in normal volunteers and in patients with OSA [22,
23]. In these studies, sympathetic activity was derived from
measurements of muscle sympathetic nerve activity. Previous
experimental studies from our group already indicated that an
elevated sympathetic nerve activity measured by microneuro-
graphy from the peroneal nerve results in an increased reflective
index [18]. In the present study, we confirmed that apnoea
increased the reflective index in a similar way to vasoconstriction
induced by the cold-pressure test. Therefore, our present results
of increased vasoconstriction are in line with previous findings
of increased sympathetic activity in patients with OSA.
Secondly, patients with OSA show endothelial dysfunction,
which predisposes to reduced vasodilatation and increased
vasoconstriction. Studies showed that patients with OSA had
lower endothelium-dependent flow-mediated dilation com-
pared with control subjects [24, 25]. Thirdly, patients with OSA
had significantly higher plasma levels of potent vasoconstrictors,
including endothelin-1 and angiotensin II, compared with
healthy controls. Furthermore, the endothelin-1 level was
significantly correlated with the AHI [26, 27]. Fourthly, patients
with OSA had significantly higher markers of oxidative stress
and inflammation, eventually leading to hypertension [28].
Increased reactive oxygen species had also been reported in
patients with OSA [29]. Increased serum concentrations of high
sensitivity C-reactive protein, interleukin-6, tumour necrosis
factor-a and malondialdehyde could be reduced during success-
ful nCPAP treatment [30].
We found a significant influence of sleep stage on the reflective
index, with lower reflective index values consistent with less
vasoconstriction in deep (delta) sleep and significantly lower
reflective index in REM sleep compared with sleep stage 1. This
might be explained by an increase of vagal tone in deep sleep
compared with stage 1 sleep and in components of REM sleep [31,
32]. A significant decrease of blood catecholamine concentration
(epinephrine and norepinephrine) during REM sleep, despite the
well-known increase of muscle sympathetic activity during this
stage, has been convincingly demonstrated and discussed by
DODT et al. [33]. According to recent guidelines, nCPAP devices
are recommended to treat patients with symptomatic OSA to
reduce their cardiovascular risk [2, 34]. The mean CPAP
adherence in our study is either in the same range or above the
values reached in comparable investigations [35–37]. According
to recent literature, mean nCPAP duration of 5–6 h predicts
normalisation of the Functional Outcomes of Sleep Questionnaire
in 68% of patients [35]. CPAP use of 5.6 h per night constitutes the
threshold for positive effects on blood pressure in nonsleepy
hypertensive patients reported by BARBE´ et al. [36] and was shown
to reduce blood pressure and nocturnal sympathetic activity [37].
The present study shows that successful treatment of OSA using
nCPAP significantly reduces vasoconstriction during the night.
Treatment with nCPAP significantly reduced sympathetic nerve
activity and norepinephrine plasma levels in patients with OSA
[14, 38]. The reduction of sympathetic nerve activity could
contribute to the reduced vasoconstriction observed in the present
study. Furthermore, previous studies showed that effective
treatment using nCPAP significantly reduced leptin in patients
with OSA [39]. As leptin is able to stimulate sympathetic
mechanisms that produce vasoconstriction, the reduced leptin
concentrations during nCPAP treatment may ameliorate vaso-
constriction [40]. Decreased sympathetic nerve activity and
decreased concentrations of vasoconstrictive mediators are pro-
bably the underlying mechanisms that finally result in the
reduced vasoconstriction we observed 6 months after starting
the nCPAP therapy; however, our study did not investigate the
underlying mechanisms or mediators. The reduction of nocturnal
vasoconstriction causes shifting of the pulse wave reflecting sites
to more peripheral areas. As outlined by SAFAR et al. [9], shifting of
the pulse wave reflecting sites to more peripheral areas improves
heart-vessel coupling and eventually results in a reduced
cardiovascular risk. We used an analytical method that allows
noninvasive, investigator-independent, automatic analysis enabl-
ing monitoring of digital volume pulse during the night. Further
studies should be performed to investigate if the observed
vascular effects under nCPAP treatment can be used to predict
cardiovascular risk reduction in individual nCPAP-treated
patients. Mean delta sleep (sleep stages 3+4) in our cohort was
.20% in asymptomatic OSA, whereas it was lower in patients
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FIGURE 4. Reflective index in 29 patients with obstructive sleep apnoea before
and 6 months after treatment with nasal continuous positive airway pressure
(nCPAP). a) Bar graph showing the reflective index during the night before nCPAP
treatment. ***: p,0.001 by Friedman test with Dunn’s multiple comparison post
hoc test compared with patients awake in the lying position before the start of the
polysomnography. b) Bar graph showing the reflective index during the night after
nCPAP treatment.
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with symptomatic OSA. Delta sleep significantly increased with
nCPAP treatment. These results are in agreement with improved
delta sleep with CPAP therapy [41, 42]; however, we cannot
exclude an overestimation in our reports of delta sleep. Interscorer
reliability has been shown to range from 65 to 78% when applying
the criteria of RECHTSCHAFFEN and KALES [20] and NORMAN et al.
[43]. All our sleep stage data were evaluated by one scorer.
Conclusion
In summary, using digital photoplethysmography we have
shown a change in the reflective index consistent with increased
vasoconstriction during the night in patients with OSA and an
AHI.10. We show that a successful therapy of symptomatic
OSA by nCPAP for 6 months is accompanied by a change in the
reflective index consistent with reduced vasoconstriction during
the night.
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